- Global Operation
- Contract Manufacturing
Apremilast is a small molecule inhibitor of PDE4, an enzyme that breaks down cyclic adenosine monophosphate (cAMP). In inflammatory cells, PDE4 is the dominant enzyme responsible for this reaction. The resulting increase in cAMP levels down regulates expression of a number of pro inflammatory factors like tumor necrosis factor alpha (TNF), interleukin 17, interleukin 23, and many others, and up regulates the anti-inflammatory interleukin 10. The specific mechanism(s) by which Apremilast exerts its therapeutic action in psoriatic arthritis patients and psoriasis patients is not well defined.
Apremilast, an inhibitor of phosphodiesterase 4 (PDE4), is indicated for the treatment of:
• Adult patients with active psoriatic arthritis
• Patients with moderate to severe plaque bpsoriasis who are candidates for phototherapy or systemic therapy.
Apemilast® Tablet 10 mg: Each commercial box contains 30 tablets in Alu-Alu blister pack.
Apemilast® Tablet 20 mg: Each commercial box contains 30 tablets in Alu-Alu blister pack.
Apemilast® Tablet 30 mg: Each commercial box contains 30 tablets in Alu-Alu blister pack.